Evidence map›Paper›PMID 25941578›Full record

ReviewOncoimmunology2014

Trial watch: IDO inhibitors in cancer therapy.

Erika Vacchelli, Fernando Aranda, Alexander Eggermont, Catherine Sautès-Fridman, Eric Tartour, Eugene P Kennedy, Michael Platten, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 325 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. iScience · 2023
    Article
  7. BIN1 in cancer: biomarker and therapeutic target.Journal of cancer research and clinical oncology · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
  18. Review
  19. Review
  20. Tryptophan potentiates CD8Journal for immunotherapy of cancer · 2021
    Article

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Erika VacchelliGustave Roussy Cancer Campus ; Villejuif, France ; INSERM U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; ; Université Paris-Sud/Paris XI; Orsay , Paris, France.
Fernando ArandaGustave Roussy Cancer Campus ; Villejuif, France ; INSERM U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ;
Alexander EggermontGustave Roussy Cancer Campus ; Villejuif, France.
Catherine Sautès-FridmanINSERM U1138 ; Paris, France ; Equipe 13; Centre de Recherche des Cordeliers ; Paris, France ; Université Pierre et Marie Curie/Paris VI ; Paris, France.
Eric TartourUniversité Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; INSERM U970 ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France.
Eugene P KennedyNewLink Genetics Co. ; Ames, IA USA.
Michael PlattenDepartment of Neurooncology; University Hospital Heidelberg and National Center for Tumor Diseases ; Heidelberg, Germany ; German Cancer Consortium (DKTK) Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center (DKFZ) ; Heidelberg, Germany.
Laurence ZitvogelGustave Roussy Cancer Campus ; Villejuif, France ; INSERM U1015; CICBT507 ; Villejuif, France.
Guido KroemerINSERM U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France ; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP ; Paris, France ; Metabolomics and Cell Biology Platforms; Gustave Roussy Cancer Campus ; Villejuif, France.
Lorenzo GalluzziGustave Roussy Cancer Campus ; Villejuif, France ; INSERM U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France ; ; Université Paris Descartes/Paris V; Sorbonne Paris Cité ; Paris, France.
Délégation Paris 5 · FRInserm · FRAmes National Laboratory · USGerman Cancer Research Center · DEInstitut Gustave Roussy · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indoleamine 2,3-dioxigenase 1 (IDO1) is the main enzyme that catalyzes the first, rate-limiting step of the so-called "kynurenine pathway", i.e., the metabolic cascade that converts the essential amino acid

Indexed as

1-methyl-D-tryptophanAHR, aryl hydrocarbon receptorBIN1, bridging integrator 1CTLA4, cytotoxic T lymphocyte associated protein 4DC, dendritic cellFDA, Food and Drug AdministrationGCN2, general control non-derepressible 2HCC, hepatocellular carcinomaIDO, indoleamine 2,3-dioxigenaseIFNγ, interferon γINCB024360indoximodinterferon γKyn, L-kynurenineNK, natural killerNLG919ODN, oligodeoxynucleotidepeptide-based anticancer vaccinesTDO2, tryptophan 2,3-dioxigenaseTLR, Toll-like receptorTreg, regulatory T cellTrp, L-tryptophan

Identifiers

PMID25941578
PMCPMC4292223
OpenAlexW2095808484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.